Escitalopram versus paroxetine controlled release in major depressive disorder

A randomized trial

Taro Kishi, Yuki Matsuda, Shinji Matsunaga, Masatsugu Moriwaki, Yoichiro Otake, Kaku Akamatsu, Tomo Okochi, Shigeki Hirano, Toshihiko Funahashi, Momoko Okuda, Hideaki Tabuse, Kiyoshi Fujita, Nakao Iwata

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: There are no direct comparisons between escitalopram and paroxetine controlled release in patients with major depressive disorder (MDD). Methods: We conducted a 24-week, rater-masked, randomized trial of escitalopram (5–20 mg/day) versus paroxetine controlled release (12.5–50 mg/day) in patients with MDD (UMIN000011191). Patients with the diagnosis of moderate-to-severe MDD (a 17-item Hamilton Rating Scale for Depression [HAMD-17], with total score at baseline being $20) were recruited to participate in a parallel, randomized, controlled trial. The primary outcome for efficacy was an improvement in the 21-item HAMD (HAMD-21) total score at 24 weeks. The secondary outcomes were the response, remission, and discontinuation rates and the incidence of individual adverse events. Results: A total of 88 patients with MDD (males, 61.4%; mean age, 40.8±13.4 years) were recruited. The discontinuation rate was 58.0% (escitalopram, 55.8%; paroxetine controlled release, 60.0%). Both escitalopram and paroxetine controlled-release treatment groups exhibited significant reduction in the HAMD-21 total score at 2, 4, 8, 12, and 24 weeks from the baseline. However, there were no significant differences in the HAMD-21 total score, response rate, remission rate, and discontinuation rate at any time point between the groups. In addition, there were no significant differences in the incidence of any individual adverse events (eg, nausea, vomiting, and somnolence) between the treatment groups. Conclusion: Our results suggest that escitalopram and paroxetine controlled release had similar efficacy and safety profiles in patients with MDD. One of the primary limitations of this study is the small sample size.

Original languageEnglish
Pages (from-to)117-125
Number of pages9
JournalNeuropsychiatric Disease and Treatment
Volume13
DOIs
Publication statusPublished - 06-01-2017

Fingerprint

Paroxetine
Citalopram
Major Depressive Disorder
Incidence
Sample Size
Nausea
Vomiting
Randomized Controlled Trials
Depression
Safety
Therapeutics

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Kishi, Taro ; Matsuda, Yuki ; Matsunaga, Shinji ; Moriwaki, Masatsugu ; Otake, Yoichiro ; Akamatsu, Kaku ; Okochi, Tomo ; Hirano, Shigeki ; Funahashi, Toshihiko ; Okuda, Momoko ; Tabuse, Hideaki ; Fujita, Kiyoshi ; Iwata, Nakao. / Escitalopram versus paroxetine controlled release in major depressive disorder : A randomized trial. In: Neuropsychiatric Disease and Treatment. 2017 ; Vol. 13. pp. 117-125.
@article{7aa058786b29495d8612b2cb617bc62c,
title = "Escitalopram versus paroxetine controlled release in major depressive disorder: A randomized trial",
abstract = "Objective: There are no direct comparisons between escitalopram and paroxetine controlled release in patients with major depressive disorder (MDD). Methods: We conducted a 24-week, rater-masked, randomized trial of escitalopram (5–20 mg/day) versus paroxetine controlled release (12.5–50 mg/day) in patients with MDD (UMIN000011191). Patients with the diagnosis of moderate-to-severe MDD (a 17-item Hamilton Rating Scale for Depression [HAMD-17], with total score at baseline being $20) were recruited to participate in a parallel, randomized, controlled trial. The primary outcome for efficacy was an improvement in the 21-item HAMD (HAMD-21) total score at 24 weeks. The secondary outcomes were the response, remission, and discontinuation rates and the incidence of individual adverse events. Results: A total of 88 patients with MDD (males, 61.4{\%}; mean age, 40.8±13.4 years) were recruited. The discontinuation rate was 58.0{\%} (escitalopram, 55.8{\%}; paroxetine controlled release, 60.0{\%}). Both escitalopram and paroxetine controlled-release treatment groups exhibited significant reduction in the HAMD-21 total score at 2, 4, 8, 12, and 24 weeks from the baseline. However, there were no significant differences in the HAMD-21 total score, response rate, remission rate, and discontinuation rate at any time point between the groups. In addition, there were no significant differences in the incidence of any individual adverse events (eg, nausea, vomiting, and somnolence) between the treatment groups. Conclusion: Our results suggest that escitalopram and paroxetine controlled release had similar efficacy and safety profiles in patients with MDD. One of the primary limitations of this study is the small sample size.",
author = "Taro Kishi and Yuki Matsuda and Shinji Matsunaga and Masatsugu Moriwaki and Yoichiro Otake and Kaku Akamatsu and Tomo Okochi and Shigeki Hirano and Toshihiko Funahashi and Momoko Okuda and Hideaki Tabuse and Kiyoshi Fujita and Nakao Iwata",
year = "2017",
month = "1",
day = "6",
doi = "10.2147/NDT.S124898",
language = "English",
volume = "13",
pages = "117--125",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",

}

Kishi, T, Matsuda, Y, Matsunaga, S, Moriwaki, M, Otake, Y, Akamatsu, K, Okochi, T, Hirano, S, Funahashi, T, Okuda, M, Tabuse, H, Fujita, K & Iwata, N 2017, 'Escitalopram versus paroxetine controlled release in major depressive disorder: A randomized trial', Neuropsychiatric Disease and Treatment, vol. 13, pp. 117-125. https://doi.org/10.2147/NDT.S124898

Escitalopram versus paroxetine controlled release in major depressive disorder : A randomized trial. / Kishi, Taro; Matsuda, Yuki; Matsunaga, Shinji; Moriwaki, Masatsugu; Otake, Yoichiro; Akamatsu, Kaku; Okochi, Tomo; Hirano, Shigeki; Funahashi, Toshihiko; Okuda, Momoko; Tabuse, Hideaki; Fujita, Kiyoshi; Iwata, Nakao.

In: Neuropsychiatric Disease and Treatment, Vol. 13, 06.01.2017, p. 117-125.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Escitalopram versus paroxetine controlled release in major depressive disorder

T2 - A randomized trial

AU - Kishi, Taro

AU - Matsuda, Yuki

AU - Matsunaga, Shinji

AU - Moriwaki, Masatsugu

AU - Otake, Yoichiro

AU - Akamatsu, Kaku

AU - Okochi, Tomo

AU - Hirano, Shigeki

AU - Funahashi, Toshihiko

AU - Okuda, Momoko

AU - Tabuse, Hideaki

AU - Fujita, Kiyoshi

AU - Iwata, Nakao

PY - 2017/1/6

Y1 - 2017/1/6

N2 - Objective: There are no direct comparisons between escitalopram and paroxetine controlled release in patients with major depressive disorder (MDD). Methods: We conducted a 24-week, rater-masked, randomized trial of escitalopram (5–20 mg/day) versus paroxetine controlled release (12.5–50 mg/day) in patients with MDD (UMIN000011191). Patients with the diagnosis of moderate-to-severe MDD (a 17-item Hamilton Rating Scale for Depression [HAMD-17], with total score at baseline being $20) were recruited to participate in a parallel, randomized, controlled trial. The primary outcome for efficacy was an improvement in the 21-item HAMD (HAMD-21) total score at 24 weeks. The secondary outcomes were the response, remission, and discontinuation rates and the incidence of individual adverse events. Results: A total of 88 patients with MDD (males, 61.4%; mean age, 40.8±13.4 years) were recruited. The discontinuation rate was 58.0% (escitalopram, 55.8%; paroxetine controlled release, 60.0%). Both escitalopram and paroxetine controlled-release treatment groups exhibited significant reduction in the HAMD-21 total score at 2, 4, 8, 12, and 24 weeks from the baseline. However, there were no significant differences in the HAMD-21 total score, response rate, remission rate, and discontinuation rate at any time point between the groups. In addition, there were no significant differences in the incidence of any individual adverse events (eg, nausea, vomiting, and somnolence) between the treatment groups. Conclusion: Our results suggest that escitalopram and paroxetine controlled release had similar efficacy and safety profiles in patients with MDD. One of the primary limitations of this study is the small sample size.

AB - Objective: There are no direct comparisons between escitalopram and paroxetine controlled release in patients with major depressive disorder (MDD). Methods: We conducted a 24-week, rater-masked, randomized trial of escitalopram (5–20 mg/day) versus paroxetine controlled release (12.5–50 mg/day) in patients with MDD (UMIN000011191). Patients with the diagnosis of moderate-to-severe MDD (a 17-item Hamilton Rating Scale for Depression [HAMD-17], with total score at baseline being $20) were recruited to participate in a parallel, randomized, controlled trial. The primary outcome for efficacy was an improvement in the 21-item HAMD (HAMD-21) total score at 24 weeks. The secondary outcomes were the response, remission, and discontinuation rates and the incidence of individual adverse events. Results: A total of 88 patients with MDD (males, 61.4%; mean age, 40.8±13.4 years) were recruited. The discontinuation rate was 58.0% (escitalopram, 55.8%; paroxetine controlled release, 60.0%). Both escitalopram and paroxetine controlled-release treatment groups exhibited significant reduction in the HAMD-21 total score at 2, 4, 8, 12, and 24 weeks from the baseline. However, there were no significant differences in the HAMD-21 total score, response rate, remission rate, and discontinuation rate at any time point between the groups. In addition, there were no significant differences in the incidence of any individual adverse events (eg, nausea, vomiting, and somnolence) between the treatment groups. Conclusion: Our results suggest that escitalopram and paroxetine controlled release had similar efficacy and safety profiles in patients with MDD. One of the primary limitations of this study is the small sample size.

UR - http://www.scopus.com/inward/record.url?scp=85010333150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010333150&partnerID=8YFLogxK

U2 - 10.2147/NDT.S124898

DO - 10.2147/NDT.S124898

M3 - Article

VL - 13

SP - 117

EP - 125

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

ER -